Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
Siyu Wu, Yi Xiao, Jinli Wei, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 7, pp. e002528-e002528
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Meng‐Ling Wu, Qianrui Huang, Yao Xie, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 303
The cGAS/STING Pathway: A Novel Target for Cancer Therapy
Yu Gan, M Kellis, Shuangze Han, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 117
Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy
Zili Zhang, Haifeng Zhou, Xiaohu Ouyang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 97
c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment
Fangyan Gao, Xin-tong Li, Kun Xu, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 79
cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer
Mengting Chen, Shibo Yu, Tineke van der Sluis, et al.
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 19
Enabling tumor-specific drug delivery by targeting the Warburg effect of cancer
Jian Zhang, Tony Pan, Jimmy Lee, et al.
Cell Reports Medicine (2025), pp. 101920-101920
Open Access | Times Cited: 2
CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes
Jie Li, Xinya Gao, Zhanqiang Zhang, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 87
Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
Joyce V. Lee, Filomena Housley, Christina Yau, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 40
The effects of MYC on tumor immunity and immunotherapy
Jiajin Li, Tingyu Dong, Zhenhua Wu, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 32
Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma
Leandro Cerchietti
Blood (2024) Vol. 143, Iss. 12, pp. 1101-1111
Open Access | Times Cited: 15
The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives
Amy J. Wisdom, Christopher A. Barker, Joe Y. Chang, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 118, Iss. 5, pp. 1404-1421
Closed Access | Times Cited: 13
Targeting MYC at the intersection between cancer metabolism and oncoimmunology
Simran Venkatraman, Brinda Balasubramanian, Chanitra Thuwajit, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 12
Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer
Wenjun Huang, Qingyun Zhu, Zhichao Shi, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 12
Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications
Jun Yin, Tiezheng Gu, Norin Chaudhry, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 11
c-Myc knockdown restores tamoxifen sensitivity in triple-negative breast cancer by reactivating the expression of ERα: the central role of miR-152 and miR-148a
Chao Dong, Yonghong Sun, Xiaoli Xu, et al.
Breast Cancer (2025)
Closed Access | Times Cited: 1
Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
Rita Ribeiro, Maria João Carvalho, João Gonçalves, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 36
MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression
Ling Deng, Li Liao, Yinling Zhang, et al.
Cancer Letters (2023) Vol. 560, pp. 216124-216124
Closed Access | Times Cited: 20
Targeting one‐carbon metabolism for cancer immunotherapy
Xinxin Ren, Xiang Wang, Guowan Zheng, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Energy metabolism pathways in breast cancer progression: The reprogramming, crosstalk, and potential therapeutic targets
Xuewei Zheng, Haodi Ma, Jingjing Wang, et al.
Translational Oncology (2022) Vol. 26, pp. 101534-101534
Open Access | Times Cited: 28
Update on triple‐negative breast cancers – highlighting subtyping update and treatment implication
Julia Y. Tsang, Gary M. Tse
Histopathology (2022) Vol. 82, Iss. 1, pp. 17-35
Closed Access | Times Cited: 26
Inhibition of DNMT1 potentiates antitumor immunity in oral squamous cell carcinoma
Shao‐Chen Yang, Wuyin Wang, Junjie Zhou, et al.
International Immunopharmacology (2022) Vol. 111, pp. 109113-109113
Closed Access | Times Cited: 23
The Role of Tumor Metabolic Reprogramming in Tumor Immunity
Xianhong Zhang, Weiguo Song, Yue Gao, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17422-17422
Open Access | Times Cited: 16
Cancer cell-specific cGAS/STING Signaling pathway in the era of advancing cancer cell biology
Vijay Kumar, Caitlin Bauer, John H. Stewart
European Journal of Cell Biology (2023) Vol. 102, Iss. 3, pp. 151338-151338
Open Access | Times Cited: 15
cGAS-STING at the crossroads in cancer therapy
Rui Wang, Aashiq Hussain, Guo Quanquan, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 193, pp. 104194-104194
Closed Access | Times Cited: 15
Nanoformulations of chemotherapeutic activators of the cGAS–STING pathway in tumor chemoimmunotherapy
Lingzhi Wang, Zhuo Yu, Jihong Zhang, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103892-103892
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top